PODD Stock Summary and Trading Ideas (Insulet | NASDAQ:PODD)

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.

Insulet trades on the NASDAQ stock market under the symbol PODD.

As of September 1, 2026, PODD stock price declined to $148.50 with 130,519 million shares trading.

PODD has a beta of -0.60, meaning it tends to be less sensitive to market movements. PODD has a correlation of 0.05 to the broad based SPY ETF.

PODD has a market cap of $10.45 billion. This is considered a Large Cap stock.

Last quarter Insulet reported $802 million in Revenue and $1.66 earnings per share. This beat revenue expectation by $14 million and exceeded earnings estimates by $.22.

In the last 3 years, PODD traded as high as $354.88 and as low as $125.82.

The top ETF exchange traded funds that PODD belongs to (by Net Assets): VTI, VOO, VB, RSP, VBK.

PODD has underperformed the market in the last year with a return of -56.3%, while SPY returned +19.7%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in PODD shares. However, PODD has outperformed the market in the last 3 month and 2 week periods, returning +2.5% and +6.3%, while SPY returned +1.3% and -1.1%, respectively. This indicates PODD has been having a stronger performance recently.

PODD support price is $144.62 and resistance is $152.70 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PODD shares will trade within this expected range on the day.